SOLVENTUM ($SOLV) posted quarterly earnings results for Q4 2025 on Thursday, February 26th. The company reported earnings of $1.57 per share, beating estimates of $1.53 by $0.04. The company also reported revenue of $1,998,000,000, missing estimates of $1,999,749,882 by $-1,749,882.
You can see Quiver Quantitative's $SOLV stock page to track data on insider trading, hedge fund activity, congressional trading, and more.
SOLVENTUM Hedge Fund Activity
We have seen 354 institutional investors add shares of SOLVENTUM stock to their portfolio, and 447 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- INDEPENDENT FRANCHISE PARTNERS LLP added 2,456,451 shares (+19.0%) to their portfolio in Q4 2025, for an estimated $194,649,177
- UBS AM, A DISTINCT BUSINESS UNIT OF UBS ASSET MANAGEMENT AMERICAS LLC removed 2,373,713 shares (-76.6%) from their portfolio in Q4 2025, for an estimated $188,093,018
- CITADEL ADVISORS LLC removed 1,442,798 shares (-92.7%) from their portfolio in Q4 2025, for an estimated $114,327,313
- DIAMOND HILL CAPITAL MANAGEMENT INC added 1,272,921 shares (+152.2%) to their portfolio in Q4 2025, for an estimated $100,866,260
- CANDLESTICK CAPITAL MANAGEMENT LP removed 947,174 shares (-100.0%) from their portfolio in Q3 2025, for an estimated $69,143,702
- GEODE CAPITAL MANAGEMENT, LLC added 763,308 shares (+20.0%) to their portfolio in Q4 2025, for an estimated $60,484,525
- NORDEA INVESTMENT MANAGEMENT AB removed 744,185 shares (-98.1%) from their portfolio in Q4 2025, for an estimated $58,969,219
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard.
SOLVENTUM Government Contracts
We have seen $15,185,368 of award payments to $SOLV over the last year.
Here are some of the awards which we have have seen pay out the most over the last year:
- SOLE SOURCE AWARD FOR RENEWAL OF SOLVENTUM HIS CRS+ ENCODER SOFTWARE LICENSES AND SUPPORT SERVICES FOR VA H...: $12,015,798
- 3M SOFTWARE: $1,664,799
- 3M GPCS SOFTWARE: $1,282,756
- 3M CODING SOFTWARE FOR HEALTH INFORMATION MANAGEMENT AND MEDICAL RECORDS: $28,412
- 3M CODING SOFTWARE FOR HEALTH INFORMATION MANAGEMENT AND MEDICAL RECORDS: $28,412
To track government contracts to publicy traded companies, check out Quiver Quantitative's government contracts dashboard.
SOLVENTUM Congressional Stock Trading
Members of Congress have traded $SOLV stock 1 times in the past 6 months. Of those trades, 0 have been purchases and 1 have been sales.
Here’s a breakdown of recent trading of $SOLV stock by members of Congress over the last 6 months:
- REPRESENTATIVE J. FRENCH HILL sold up to $50,000 on 12/31.
To track congressional stock trading, check out Quiver Quantitative's congressional trading dashboard.
SOLVENTUM Analyst Ratings
Wall Street analysts have issued reports on $SOLV in the last several months. We have seen 3 firms issue buy ratings on the stock, and 0 firms issue sell ratings.
Here are some recent analyst ratings:
- Keybanc issued a "Overweight" rating on 01/26/2026
- Mizuho issued a "Outperform" rating on 01/20/2026
- Piper Sandler issued a "Overweight" rating on 11/07/2025
To track analyst ratings and price targets for SOLVENTUM, check out Quiver Quantitative's $SOLV forecast page.
SOLVENTUM Price Targets
Multiple analysts have issued price targets for $SOLV recently. We have seen 8 analysts offer price targets for $SOLV in the last 6 months, with a median target of $97.5.
Here are some recent targets:
- Brett Fishbin from Keybanc set a target price of $97.0 on 01/26/2026
- Steven Valiquette from Mizuho set a target price of $100.0 on 01/20/2026
- Rick Wise from Stifel set a target price of $105.0 on 01/07/2026
- Ryan Zimmerman from BTIG set a target price of $100.0 on 12/02/2025
- Kevin Caliendo from UBS set a target price of $79.0 on 11/10/2025
- Jason Bednar from Piper Sandler set a target price of $98.0 on 11/07/2025
- Vik Chopra from Wells Fargo set a target price of $82.0 on 09/15/2025
This article is not financial advice. See Quiver Quantitative's disclaimers for more information. Note that there may be inaccuracies due to mistakes in ticker-mapping, and other anomalies.
